NORTH-REG Dwell-Time Study

Side Effect of Drug Clinical Trial

Official title:

Nordic Urothelial Cancer Research Group Study on Reduced BCG Dwell-Time in High Risk NMIBC

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04701151
• Other study ID #: 2020-003112-27
• Status: Recruiting
• Phase: Phase 4
• Start date: February 3, 2021
• Est. completion date: December 2030

Study information

• Verified date: December 2023
• Source: Aarhus University Hospital
• Contact: Jørgen B. Jensen, Professor,DMSc
• Phone: +45 78452617
• Email: Bjerggaard[@]skejby.rm.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations. This will increase their risk of recurrence and potential cystectomy. The purpose of this study is to investigate if NMIBC patients who experience severe side effects to BCG instillations will experience fewer or less severe side effects if reducing dwell-time of BCG instillations.

The study will include patients from Denmark, Iceland, Norway and Sweden.

Description:

Approximately 8,000 patients are diagnosed with bladder cancer (BC) in the Nordic countries every year. The majority of BC patients are diagnosed with non-muscle invasive bladder cancer (NMIBC). The majority of NMIBC are treated with Bacillus Calmette-Guérin vaccine (BCG) as adjuvant treatment but for carcinoma in situ it is the primary treatment. BCG is known to give a lot of side effects both local and systemic, the severity of these can lead to premature termination of the treatment.

The object of this PhD project is to investigate if reduced dwell time, the time the BCG is in the bladder, will decrease the severity of side effects due to BCG instillations.

This will be investigated in a Nordic setting and the project will be done as a two-armed randomized clinical trial.

By decreasing the severity of side effects, we hypothesize the number of patients completing all planned instillations will increase and thereby decrease the risk of the BC evolving into a more aggressive type.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 314
• Est. completion date: December 2030
• Est. primary completion date: December 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• =18 years of age at the time of signing the Informed Consent Form

• Signed Informed Consent Form

• Patients with NMIBC where BCG therapy including maintenance for 1 year is planned for one of the following histopathological findings:

• Ta high grade without CIS

• CIS with or without previous or concomitant Ta tumors

• T1 with or without CIS

• Is, according to the Investigator's judgement, able to comply with the trial protocol

• Ability to understand the Patient Information Sheet orally and in writing

Exclusion Criteria:

• Previous BCG instillations within the last 2 years, because of the risk of not having cleared potential previos side effects.

• T1 tumors where re-resection had not been performed

• TUR-B, bladder biopsy or traumatic catheterization within 2 weeks.

• Previous or current MIBC

• Progression defined as progrssion to T1-tumour, T2+_tumour or cystectomy irrespectievely of indication or development of metastatic urothelial cancer irrespectively of tumour stage

• Contraindications to BCG

• Incontinence

• Bilateral nephrostomy catheters; unilateral nephrostomy catheter is allowed if permanent for the duration of all inistallations with BCG and a normally functioning kidney.

• Need for catheter a demeure at the time of instillation

• Immune Suppressing medication (cancer therapy e.g cytostatic medicinal products, radiation, local and systemic steroids like e.g. prednisolone is permitted)

• Reduced immune response (leukaemia, lymphoma)

• Known allergy or sensitivity to BCG

• HIV infection

• Signs of active tuberculosis

• Any type of previosly radiation therapy involving the bladder.

• Concomitant invasive cancer within 5 years other than non-melanoma skin cancer and protate cancer without metastasis

• Current urinary tract infection

• Patient with visible hematuria

• Current alcohol and/or drug abuse

• Has a mental or legal incapacitation or another condition which impair the subject's ability to participate

• Has participated in another interventional clinical study and treatment with another investigational product 30 days prior to randomization

• For women study subjects: Pregnancy or breastfeeding

• For women Study subjects of childbearing potential: unless they are using highly effective methods of contraception from the first BCG instillations until 14 days after last dose of BCG treatment, which are defined as total abstinence, female sterilization, use of oral methods of contraception or placement of an intrauterine contraception devices.

• For male Study Subjects: unless they are using highly effective methods of contraception from the first BCG instillation until for 14 days after last dose of BCG treatment, which is defined as total abstinence or use of condoms.

Related Conditions & MeSH terms

• Drug-Related Side Effects and Adverse Reactions
• Side Effect of Drug

Intervention

Drug:
• Bacillus Calmette Guerin
The same dose of the drug will be given in both arms but the dwell-time will be adjusted for the subjects in the intervention arm according to the grading of side effects given by the study algorithm.

Locations

Country	Name	City	State
Denmark	Department of Urology, Aalborg University Hospital	Aalborg
Denmark	Aarhus University Hospital	Aarhus	Aarhus N
Denmark	Herlev Hospital	Herlev
Denmark	Regional Hospital Gødstrup	Herning
Denmark	Department of Urology, Rigshospitalet	København
Denmark	Odense University Hospital	Odense
Denmark	Zealand University Hospital	Roskilde
Iceland	Landspitali University Hospital	Reykjavík
Sweden	PO Sahlgrenska Universitetssjukhuset	Göteborg
Sweden	Örebro University Hospital	Örebro
Sweden	Karolinska University Hospital	Stockholm

Sponsors (12)

Lead Sponsor	Collaborator
Jørgen Bjerggaard Jensen	Aalborg University Hospital, Aarhus University Hospital, Herlev Hospital, Karolinska University Hospital, Landspitali University Hospital, Odense University Hospital, Region Örebro County, Regional Hospital West Jutland, Rigshospitalet, Denmark, Sahlgrenska University Hospital, Sweden, Zealand University Hospital

Countries where clinical trial is conducted

Denmark,  Iceland,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Completion of instillations	Number of Study Subjects completing all 6 induction instillations and subsequent maintenance installations for 12 months (6 + 3 x 3)	5 years
Secondary	Recurrence rate	Recurrence rate within 24 months in Study Subjects with initial complete response	5 years